Golgi Pharmaceuticals expands marketing
Golgi Pharmaceuticals of Cyprus is strengthening its collaboration with London-based ReGen Therapeutics. Golgi will produce tablets of and package Colostrinin, and expand distribution to Greece and other Balcan countries. Colostrinin is a proline-rich polypeptide complex derived from mammalian colostrum. The complex and peptides within it could have a potential use in neurodegenerative illnesses such as Alzheimer’s disease, Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis according to clinical studies conducted in Poland in the year 2002.
To date, Colostrinin is marketed in the US, Canada and Australia under the brand name CogniSure and in Cyprus under the brand name Cognase as a nutritional supplement to support healthy brain aging and cognition in humans. It is currently being test marketed in Poland under the brand name CogniSure prior to a full launch in that country. Golgi Pharmaceuticals is based in Nicosia, Cyprus, and specialises in the national distribution of pharmaceuticals and nutraceuticals. Cyprus was the first EU state, in which Colostrinin became available in 2008.